TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Long QT Syndrome Market, by Type
6.1 Introduction
6.2 Long QT Syndrome Type 1 (LQT1)
Market Estimates & Forecast, 2020 – 2027
6.3 Long QT Syndrome Type 2 (LQT2)
Market Estimates & Forecast, 2020 – 2027
6.4 Long QT Syndrome Type 3 (LQT3)
Market Estimates & Forecast, 2020 – 2027
6.5 Others
Chapter 7. Global Long QT Syndrome Market, by Diagnosis
7.1 Introduction
7.2 Tests
Market Estimates & Forecast, 2020 – 2027
7.2.1 Serum Potassium Level Tests
7.2.2 Magnesium Level Tests
7.2.3 Others
7.3 Electrocardiogram (ECG)
Market Estimates & Forecast, 2020 – 2027
7.3.1 Holter Monitor
7.3.2 Event Monitor
7.3.3 Others
7.4 Genetic Testing
Market Estimates & Forecast, 2020 – 2027
7.5 Others
Chapter 8. Global Long QT Syndrome Market, by Treatment
8.1 Introduction
8.2 Medications
Market Estimates & Forecast, 2020 – 2027
8.2.1 Beta Blockers
8.2.1.1 Nadolol
8.2.1.2 Propranolol
8.2.1.3 Others
8.2.2 Mexiletine
8.2.3 Others
8.3 Surgical Procedures
Market Estimates & Forecast, 2020 – 2027
8.3.1 Left Cardiac Sympathetic Denervation Surgery
8.3.2 Implantable Cardioverter-Defibrillator (ICD)
8.3.3 Others
8.4 Others
Chapter 9 Global Long QT Syndrome Market, by End User
9.1 Introduction
9.2 Hospitals & Clinics
Market Estimates & Forecast, 2020 – 2027
9.3 Diagnostic Labs
Market Estimates & Forecast, 2020 – 2027
9.4 Research Organizations
Market Estimates & Forecast, 2020 – 2027
9.5 Others
Chapter 10. Global Long QT Syndrome Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 U.K
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
Chapter 11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
Chapter 12 Company Profiles
12.1 Aralez Pharmaceuticals Inc.
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials Overview \
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.2 Asper Biogene
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 AstraZeneca
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Boston Scientific Corporation
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Cipla Inc.
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 GeneDx.
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.7 Invitae Corporation
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Laboratory Corporation of America Holdings
12.8.1 Overview
12.8.2 Product Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 Lupin Pharmaceuticals, Inc.
12.9.1 Overview
12.9.2 Product Overview
12.9.3 Financials
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.10 Mylan N.V.
12.10.1 Overview
12.10.2 Product Overview
12.10.3 Financials
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.11 Pfizer Inc.
12.11.1 Overview
12.11.2 Product Overview
12.11.3 Financials
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.12 Teva Pharmaceutical Industries Ltd.
12.12.1 Overview
12.12.2 Product Overview
12.12.3 Financials
12.12.4 Key Developments
12.12.5 SWOT Analysis
12.13 Torrent Pharmaceuticals Limited
12.13.1 Overview
12.13.2 Product Overview
12.13.3 Financials
12.13.4 Key Developments
12.13.5 SWOT Analysis
12.14 Zydus Pharmaceuticals, Inc.
12.14.1 Overview
12.14.2 Product Overview
12.14.3 Financials
12.14.4 Key Developments
12.14.5 SWOT Analysis
12.15 Others
Chapter 13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Long QT Syndrome Industry
Chapter 14 Appendix
LIST OF TABLES
Table 1 Long QT Syndrome Industry Synopsis, 2020 – 2027
Table 2 Global Long QT Syndrome Market Estimates and Forecast, 2020 – 2027, (USD Million)
Table 3 Global Long QT Syndrome Market by Region, 2020 – 2027, (USD Million)
Table 4 Global Long QT Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 5 Global Long QT Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 6 Global Long QT Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 7 Global Long QT Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 8 North America Long QT Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 9 North America Long QT Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 10 North America Long QT Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 11 North America Long QT Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 12 U.S. Long QT Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 13 U.S. Long QT Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 14 U.S. Long QT Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 15 U.S. Long QT Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 16 Canada Long QT Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 17 Canada Long QT Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 18 Canada Long QT Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 19 Canada Long QT Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 20 South America Long QT Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 21 South America Long QT Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 22 South America Long QT Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 23 South America Long QT Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 24 Europe Long QT Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 25 Europe Long QT Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 26 Europe Long QT Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 27 Europe Long QT Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 28 Western Europe Long QT Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 29 Western Europe Long QT Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 30 Western Europe Long QT Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 31 Western Europe Long QT Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 32 Eastern Europe Market by Type, 2020 – 2027, (USD Million)
Table 33 Eastern Europe Long QT Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 34 Eastern Europe Long QT Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 35 Eastern Europe Long QT Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 36 Asia Pacific Long QT Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 37 Asia Pacific Long QT Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 38 Asia Pacific Long QT Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 39 Asia Pacific Long QT Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 40 Middle East & Africa Long QT Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 41 Middle East & Africa Long QT Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 42 Middle East & Africa Long QT Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 43 Middle East & Africa Long QT Syndrome Market by End User, 2020 – 2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Long QT Syndrome Market
Figure 3 Market Dynamics for Global Long QT Syndrome Market
Figure 4 Global Long QT Syndrome Market Share, by Type 2020
Figure 5 Global Long QT Syndrome Market Share, by Diagnosis 2020
Figure 6 Global Long QT Syndrome Market Share, by Treatment 2020
Figure 7 Global Long QT Syndrome Market Share, by End User, 2020
Figure 8 Global Long QT Syndrome Market Share, by Region, 2020
Figure 9 North America Long QT Syndrome Market Share, by Country, 2020
Figure 10 Europe Long QT Syndrome Market Share, by Country, 2020
Figure 11 Asia Pacific Long QT Syndrome Market Share, by Country, 2020
Figure 12 Middle East & Africa Long QT Syndrome Market Share, by Country, 2020
Figure 13 Global Long QT Syndrome Market: Company Share Analysis, 2020 (%)
Figure 14 Aralez Pharmaceuticals Inc.: Key Financials
Figure 15 Aralez Pharmaceuticals Inc.: Segmental Revenue
Figure 16 Aralez Pharmaceuticals Inc.: Geographical Revenue
Figure 17 Asper Biogene: Key Financials
Figure 18 Asper Biogene: Segmental Revenue
Figure 19 Asper Biogene: Geographical Revenue
Figure 20 AstraZeneca: Key Financials
Figure 21 AstraZeneca: Segmental Revenue
Figure 22 AstraZeneca: Geographical Revenue
Figure 23 Boston Scientific Corporation: Key Financials
Figure 24 Boston Scientific Corporation: Segmental Revenue
Figure 25 Boston Scientific Corporation: Geographical Revenue
Figure 26 Cipla Inc.: Key Financials
Figure 27 Cipla Inc.: Segmental Revenue
Figure 28 Cipla Inc.: Geographical Revenue
Figure 29 GeneDx.: Key Financials
Figure 30 GeneDx.: Segmental Revenue
Figure 31 GeneDx.: Geographical Revenue
Figure 32 Invitae Corporation: Key Financials
Figure 33 Invitae Corporation: Segmental Revenue
Figure 34 Invitae Corporation: Geographical Revenue
Figure 35 Laboratory Corporation of America Holdings: Key Financials
Figure 36 Laboratory Corporation of America Holdings: Segmental Revenue
Figure 37 Laboratory Corporation of America Holdings: Geographical Revenue
Figure 38 Lupin Pharmaceuticals, Inc.: Key Financials
Figure 39 Lupin Pharmaceuticals, Inc.: Segmental Revenue
Figure 40 Lupin Pharmaceuticals, Inc.: Geographical Revenue
Figure 41 Mylan N.V.: Key Financials
Figure 42 Mylan N.V.: Segmental Revenue
Figure 43 Mylan N.V.: Geographical Revenue
Figure 44 Pfizer Inc.: Key Financials
Figure 45 Pfizer Inc.: Segmental Revenue
Figure 46 Pfizer Inc.: Geographical Revenue
Figure 47 Teva Pharmaceutical Industries Ltd.: Key Financials
Figure 48 Teva Pharmaceutical Industries Ltd.: Segmental Revenue
Figure 49 Teva Pharmaceutical Industries Ltd.: Geographical Revenue
Figure 50 Torrent Pharmaceuticals Limited: Key Financials
Figure 51 Torrent Pharmaceuticals Limited: Segmental Revenue
Figure 52 Torrent Pharmaceuticals Limited: Geographical Revenue
Figure 53 Zydus Pharmaceuticals, Inc.: Key Financials
Figure 54 Zydus Pharmaceuticals, Inc.: Segmental Revenue
Figure 55 Zydus Pharmaceuticals, Inc.: Geographical Revenue
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
